Relationship between waist-to-height ratio and heart failure outcome: A single-centre prospective cohort study

Ping Wang1, Yang Zhao1, Danni Wang2

  • 1Department of Cardiology, Xijing Hospital, Air Force Medical University, Xi'an, China.

ESC Heart Failure
|September 17, 2024
PubMed

Insights

Waist-to-height ratio (WHtR) indicates higher mortality risk in heart failure with reduced ejection fraction (HFrEF) patients, but not in those with preserved ejection fraction (HFpEF), suggesting an obesity paradox in HFrEF.

Area of Science:

  • Cardiology
  • Metabolic Health
  • Public Health

Background:

  • Waist-to-height ratio (WHtR) is an indicator of central obesity.
  • Central obesity is linked to cardiovascular disease and heart failure (HF).
  • The prognostic value of WHtR in HF across different ejection fraction (EF) categories requires further investigation.

Purpose of the Study:

  • To assess the correlation between WHtR and HF outcomes.
  • To evaluate if this correlation differs between heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).

Main Methods:

  • Prospective cohort study of 859 HF patients.
  • Participants categorized by WHtR and EF quartiles.
  • Cox proportional hazard regression used to analyze associations between WHtR and 48-month all-cause mortality.

Main Results:

  • High WHtR (≥0.50) correlated with higher prevalence of hypertension, diabetes, and adverse lipid profiles.
  • Low WHtR (<0.50) was associated with increased all-cause and cardiovascular mortality compared to high WHtR.
  • HFrEF patients with low WHtR had a significantly elevated risk of all-cause, HF, and non-cardiovascular mortality.
  • WHtR had a negligible effect on mortality risk in HFpEF patients.

Conclusions:

  • An obesity paradox, indicated by WHtR, is present in HFrEF patients.
  • This paradox is absent in HFpEF patients.
  • WHtR may serve as a prognostic marker in HFrEF.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
96
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
350
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398